Japanese Researchers Identify NOX-1 Enzyme as Key to Extending Ketamine’s Rapid Antidepressant Effects

Yokohama City University researchers identify NOX-1 as a molecular target to extend ketamine's antidepressant effects from days to weeks.

By: AXL Media

Published: Mar 30, 2026, 10:36 AM EDT

Source: Information for this report was sourced from Yokohama City University

Overcoming the Transient Nature of Ketamine Relief

Ketamine has revolutionized the treatment of major depressive disorder, particularly for the millions who suffer from treatment-resistant depression (TRD). Unlike traditional antidepressants that require weeks to take effect, ketamine provides relief within hours. However, its primary clinical limitation is its short duration; the antidepressant effects typically vanish within days or a few weeks. Led by Professor Takuya Takahashi, researchers at Yokohama City University sought to uncover the molecular "off-switch" that causes these benefits to fade so quickly, aiming to develop a more durable therapeutic strategy.

The Discovery of NOX-1 as a Molecular Regulator

The research team initially developed a novel compound, K-4, designed to enhance the activity of AMPA receptors (AMPARs)—proteins essential for excitatory communication between neurons. In trials using Wistar Kyoto rats, K-4 produced antidepressant effects that lasted at least 14 days, far outperforming standard ketamine. Analysis of the medial prefrontal cortex (mPFC) revealed that this sustained relief was directly linked to lower levels of NADPH oxidase-1 (NOX-1). This enzyme produces reactive oxygen species that can disrupt brain circuits; when NOX-1 levels are high, the antidepressant "window" created by ketamine appears to close prematurely.

Stabilizing Neural Circuits Through Enzyme Inhibition

To validate NOX-1 as a primary target, the team combined standard ketamine with a pharmacological NOX-1 inhibitor. This combination successfully mirrored the long-lasting results of the K-4 compound. On a circuit level, the researchers observed that inhibiting NOX-1 reduced abnormal "burst firing" in the lateral habenula—a brain region often called the "disappointment center" because of its link to negative mood states. By dampening this overactivity and restoring the balance of excitatory and inhibitory signals in the mPFC, the treatment created a stable environment for sustained mood improvement.